HER2 Support Group Forums - View Single Post - Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening

MJsHusband · 06-06-2012, 09:06 AM

"Median progression-free survival was longer in patients treated with T-DM1 than in those treated with the standard therapy (9.6 vs 6.4 months). The difference reached is statistically significant?"

MJ is currently on Tykerb/Xeloda. So, T-DM1 would baically give a median 3.2 month extension of time without progression of disease compared to what she is already on. Statistically, that looks great at a 33% improvement but in terms of keeping the disease at bay, it's only a matter of months for many patients. I'm trying not to sound negative but I need to understand more about how a median gain of 3.2 months is remarkable(+33% is remarkable, yes). T-DM1 is being hailed as another miracle drug and I hope everyone is right because that will be our next step after Tykerb/Xeloda, I'm imagining. I'm hoping it proves to increase overall survivability. That's the important statistic for me.

Greg

06-06-2012, 09:06 AM	#7
MJsHusband Senior Member Join Date: Apr 2012 Posts: 87	Re: Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening "Median progression-free survival was longer in patients treated with T-DM1 than in those treated with the standard therapy (9.6 vs 6.4 months). The difference reached is statistically significant?" MJ is currently on Tykerb/Xeloda. So, T-DM1 would baically give a median 3.2 month extension of time without progression of disease compared to what she is already on. Statistically, that looks great at a 33% improvement but in terms of keeping the disease at bay, it's only a matter of months for many patients. I'm trying not to sound negative but I need to understand more about how a median gain of 3.2 months is remarkable(+33% is remarkable, yes). T-DM1 is being hailed as another miracle drug and I hope everyone is right because that will be our next step after Tykerb/Xeloda, I'm imagining. I'm hoping it proves to increase overall survivability. That's the important statistic for me. Greg __________________ 08/10 ~ Dx IBC, Her2+++ ER-/PR- Stage 4, mets to liver. Age 43. 08/10 ~ Began 12 weeks of Taxetere/Carboplatin/Herceptin tx [10/10 ~ Scans show liver lesions are gone. NED! 11/10 ~ Ended chemo. Herceptin-only tx 01/11 ~ Mastectomy 03/11 ~ Radiation 07/11 ~ Reconstructive surgery 10/11 ~ PET/CT shows NED :) 01/12 ~ Malignant tumors found in uterus, cervix, fallopian tubes and lymph nodes. Dx as endometrial cancer. Stage III2c 02/12 ~Hysterectomy(all tumors removed). Back to NED. 02/12 ~ Final Herceptin treatment. 03/12 ~ Began Cisplatin/Adriamycin tx for endometrial cancer. 03/12 ~ Tumors dx her2 metastisis, not entdometrial cancer. Back to BC tx. 03/12 ~ CT scan shows NED. :) 04/12/~ Began Tykerb/Xeloda. 06/12 ~ Ended Xeloda. Continuing Tykerb. Still NED. 09/12 ~ PET/CT scans show NED. : ) 04/13 ~ Rash on original breast biopsied as cancer. 05/13 ~ Surgery to remove skin and tissue around rash. Continue Tykerb. 06/13 ~ PET/CT scans show NED : ) 11/13 ~ Jaundice eyes and skin. CT scan show mets to liver as well as peritoneal carcinomatosis with malignant ascites. Began Abraxane/Herceptin tx. 02/14 ~ CT scan shows NED. :)